Recent Updates
Recently added Catalysts

Indinavir

Phase 3

HIV Infections | Small molecule | Infectious Disease |Merck & Company, Inc.|Last Updated: Jun 24, 2005

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials7
Total Enrollment918

FDA Designations

No designations recorded

Clinical trial landscape

Indinavir · 7 trials · 1 indication

Phase 3 4Phase 2 2Phase 1 1
NCT00002208A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TCHIV Infections
COMPLETED400 Analytics
NCT00002220Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With NelfinavirHIV Infections
COMPLETED120 Analytics
NCT00002406A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected PatientsHIV Infections
COMPLETED350 Analytics
NCT00002410A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected PatientsHIV Infections
COMPLETED- Analytics
PHASE3COMPLETED
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
HIV InfectionsUnlock trial analytics
PHASE3COMPLETED
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
HIV InfectionsUnlock trial analytics
PHASE3COMPLETED
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
HIV InfectionsUnlock trial analytics
PHASE3COMPLETED
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
HIV InfectionsUnlock trial analytics

Study Design & Arms

PurposeTREATMENT

Interventions

NameTypeDescription
Indinavir sulfateDRUG -
LamivudineDRUG -
StavudineDRUG -
ZidovudineDRUG -
EfavirenzDRUG -
LevocarnitineDRUG -
Adefovir dipivoxilDRUG -
Nelfinavir mesylateDRUG -
RitonavirDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range16 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites15

Inclusion Criteria Patients must have: * HIV-1 seropositive status. * CD4 count greater than 100 cells/mm3. * Viral RNA above 10,000 copies/mL. * Consent from parent or guardian if less than 18 years of age. Exclusion Criteria Prior Medication: Excluded: * Prior therapy with protease inhibitor...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria

Frequently asked questions about Indinavir

What is Indinavir used for?

Indinavir is used for the treatment of HIV infections. It is a small molecule drug being developed by Merck & Company, Inc. (MRK) and is currently in Phase 3 clinical development for this indication.

What does Indinavir target?

Indinavir is a protease inhibitor used in HIV therapy. It works by inhibiting the HIV protease enzyme, which is essential for the virus to mature and become infectious. This mechanism helps reduce viral load in HIV-positive patients.

Who makes Indinavir?

Indinavir is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 3 clinical trials for HIV infections.

What phase is Indinavir in?

Indinavir is in Phase 3 clinical development for the treatment of HIV infections. It is an investigational drug and has not yet been approved by regulatory authorities. The development program includes completed trials across Phase 1, Phase 2, and Phase 3.

What clinical trials is Indinavir in?

Indinavir has been studied in seven clinical trials, all of which are completed. Key trials include NCT00002235 (Phase 2, n=6), NCT00002351 (Phase 1, n=12), NCT00002361 (Phase 2, n=30), and NCT00002406 (Phase 3, n=350). All trials were conducted in the United States.

Is Indinavir the same as Crixivan?

Indinavir is also known by the brand name Crixivan. This alternative name is used to refer to the same drug, which is being developed by Merck & Company, Inc. for the treatment of HIV infections.